CARsgen Therapeutics (HKG:2171) recorded positive results for the confirmatory phase 2 clinical trial of Satri-cel, a candidate drug for the treatment of gastric, gastroesophageal junction, and pancreatic cancer, a Monday Hong Kong bourse filing said.
The study evaluated the safety and efficacy of satricabtagene autoleucel or satri-cel, CT041 in patients with advanced gastric or gastroesophageal junction cancers.
The study, including the assessment by the Independent Review Committee, showed an elevated progression-free survival rate for the patients treated with satri-cel compared to other treatment choices in the market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。